> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# X4 Pharma Gets Priority Review Voucher
- URL: https://www.fdaweb.com/x4-pharma-gets-priority-review-voucher/
- Published: 2024-05-16T12:00:00.000Z
- Updated: 2026-09-14T14:31:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156994

*Federal Register* notice: FDA is announcing the issuance of a priority review voucher to X4 Pharmaceuticals in response to gaining approval of a rare pediatric disease product application — Xolremdi (mavorixafor), indicated for treating patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis). To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-05-16/pdf/2024-10715.pdf?ref=fdaweb.com).